CA2631646C - Methods of reducing adverse events associated with pirfenidone therapy - Google Patents

Methods of reducing adverse events associated with pirfenidone therapy Download PDF

Info

Publication number
CA2631646C
CA2631646C CA2631646A CA2631646A CA2631646C CA 2631646 C CA2631646 C CA 2631646C CA 2631646 A CA2631646 A CA 2631646A CA 2631646 A CA2631646 A CA 2631646A CA 2631646 C CA2631646 C CA 2631646C
Authority
CA
Canada
Prior art keywords
pirfenidone
food
patient
administration
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2631646A
Other languages
English (en)
French (fr)
Other versions
CA2631646A1 (en
Inventor
Cynthia Y. Robinson
Jeffery Stuart Loutit
Michelle M. Freemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2631646(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CA2631646A1 publication Critical patent/CA2631646A1/en
Application granted granted Critical
Publication of CA2631646C publication Critical patent/CA2631646C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CA2631646A 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy Active CA2631646C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
US60/741,976 2005-12-02
PCT/US2006/045750 WO2007064738A1 (en) 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy

Publications (2)

Publication Number Publication Date
CA2631646A1 CA2631646A1 (en) 2007-06-07
CA2631646C true CA2631646C (en) 2016-07-26

Family

ID=37807840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2631646A Active CA2631646C (en) 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy

Country Status (13)

Country Link
US (1) US20070203202A1 (enExample)
EP (2) EP2316453B1 (enExample)
JP (3) JP5175740B2 (enExample)
AT (1) ATE497766T1 (enExample)
CA (1) CA2631646C (enExample)
CY (1) CY1111355T1 (enExample)
DE (1) DE602006020070D1 (enExample)
DK (1) DK1965797T3 (enExample)
ES (2) ES2385935T3 (enExample)
PL (1) PL1965797T3 (enExample)
PT (1) PT1965797E (enExample)
SI (1) SI1965797T1 (enExample)
WO (1) WO2007064738A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
EP2124945B1 (en) * 2006-12-18 2011-04-20 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
KR101767849B1 (ko) 2007-06-20 2017-08-11 오스펙스 파마슈티칼스, 인코포레이티드 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
SG172981A1 (en) * 2009-01-26 2011-08-29 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
DK2670242T3 (da) 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
JP2014507474A (ja) * 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR102045723B1 (ko) * 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 흡입용 의약 조성물
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
WO2014151517A1 (en) 2013-03-15 2014-09-25 Intermune, Inc. Methods of improving microvascular integrity
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
KR100777169B1 (ko) * 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
US20070032457A1 (en) * 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
PL1965797T3 (pl) 2011-07-29
EP1965797A1 (en) 2008-09-10
DK1965797T3 (da) 2011-05-02
US20070203202A1 (en) 2007-08-30
DE602006020070D1 (de) 2011-03-24
CY1111355T1 (el) 2015-08-05
JP2009518293A (ja) 2009-05-07
JP2012229275A (ja) 2012-11-22
ATE497766T1 (de) 2011-02-15
WO2007064738A1 (en) 2007-06-07
PT1965797E (pt) 2011-05-12
ES2385935T3 (es) 2012-08-03
EP2316453B1 (en) 2016-01-06
EP2316453A1 (en) 2011-05-04
HK1123213A1 (en) 2009-06-12
ES2565190T3 (es) 2016-04-01
JP5175740B2 (ja) 2013-04-03
EP1965797B1 (en) 2011-02-09
SI1965797T1 (sl) 2011-03-31
HK1151726A1 (en) 2012-02-10
JP2015061888A (ja) 2015-04-02
CA2631646A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
US20140221434A1 (en) Altering pharmacokinetics of pirfenidone therapy
CA2631646C (en) Methods of reducing adverse events associated with pirfenidone therapy
EP2431025A1 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
EP2509418A1 (en) Methods and low dose regimens for treating red blood cell disorders
AU2015204192B2 (en) Dosage regimen of ferric trimaltol
KR20140082858A (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
AU2014332200A1 (en) HIV treatment formulation of atazanavir and cobicistat
WO2014020344A1 (en) Compounds and their effects on appetite control and insulin sensitivity
TW201200139A (en) Oral B12 therapy
HK1151726B (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
HK1123213B (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
US20220133717A1 (en) Rabeximod in the treatment of rheumatoid arthritis
CZ79593A3 (en) Antitussive preparation
CN101972230A (zh) 吡非尼酮干混悬剂及制备
JPWO2008136173A1 (ja) スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤
JP5329866B2 (ja) 医薬組成物及び関節障害の予防治療剤
CN117138047B (zh) Tlr4抑制剂在制备缓解索拉非尼所致胃肠道毒性的药物中的应用
Tablets et al. Pr SANDOZ SAXAGLIPTIN
Agent APOTEX INC. DATE OF PREPARATION: 150 Signet Drive January 6, 2012 Weston, Ontario
Capsules et al. Pr ESBRIET™
Agent PrTEVA-SAXAGLIPTIN
Agent KOMBOGLYZE®
WO2018092085A1 (ru) Фармацевтическая композиция для лечения туберкулеза
AU2004280108A1 (en) Methods and means for modulating lipid metabolism

Legal Events

Date Code Title Description
EEER Examination request